12,674 results match your criteria Psoriatic Arthritis

Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study.

Rheumatol Ther 2022 May 20. Epub 2022 May 20.

Division of Rheumatology, Department of Medicine, Sørlandet Hospital, Service Box 416, 4604, Kristiansand, Norway.

Introduction: We aimed to compare demographics and clinical characteristics between patients with inflammatory arthritis (IA) with vs. without neutralizing anti-drug antibodies (nADAb) against tumor necrosis factor inhibitors (TNFi). A secondary aim of the study was to explore if current smokers were more frequently nADAb-positive. Read More

View Article and Full-Text PDF

Total-Body F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations.

J Nucl Med 2022 May 19. Epub 2022 May 19.

University of California Davis, United States.

Autoimmune inflammatory arthritides (AIA), such as psoriatic arthritis (PsA) and rheumatoid arthritis (RA), are chronic systemic conditions that affect multiple joints of the body. Recently, total-body (TB) PET/CT scanners have become available that exhibit superior technical characteristics (total-body coverage, geometric sensitivity) that could benefit AIA evaluation, compared to conventional PET/CT systems. The objectives of this work were to (1) assess the performance of an ultra-low-dose, F-FDG TB-PET/CT acquisition protocol for evaluating systemic joint involvement in AIA; and (2) report the association of TB-PET/CT measures with joint-by-joint rheumatologic examination and standardized rheumatologic outcome measures. Read More

View Article and Full-Text PDF

Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis.

Ann Rheum Dis 2022 May 19. Epub 2022 May 19.

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article and Full-Text PDF

Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA).

Rheumatol Ther 2022 May 17. Epub 2022 May 17.

Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Introduction: Psoriatic arthritis (PsA) is a common inflammatory disease affecting the peripheral and axial skeleton. History of psoriasis (PSO), either personal or family history, is an important factor in the diagnosis of PsA. We investigated the association between history of PSO and clinical characteristics of PsA. Read More

View Article and Full-Text PDF

Therapy of psoriasis during pregnancy and breast-feeding.

J Dtsch Dermatol Ges 2022 05;20(5):653-683

Department and Clinic for Dermatology and Allergology, University Hospital Bonn, Germany.

There have been multiple systemic drugs approved for the therapy of psoriasis vulgaris and psoriasis arthritis (PsA) in the last decade. However, treatment decisions are difficult to make in women planning a pregnancy and in pregnant and lactating women due to the paucity of data for such cases. The strongest evidence for psoriasis therapy during pregnancy exists for topical corticosteroids. Read More

View Article and Full-Text PDF

Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial.

Arthritis Res Ther 2022 May 16;24(1):111. Epub 2022 May 16.

CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany.

Objective: To investigate the imaging characteristics and clinically assess heel enthesitis in spondyloarthritis (SpA) by applying in a post hoc analysis the Heel Enthesitis Magnetic Resonance Imaging Scoring system (HEMRIS) in blinded and centrally-read MRI data from the ACHILLES trial (NCT02771210).

Methods: ACHILLES included patients (≥18 years) with active psoriatic arthritis or axial SpA with clinical and MRI-positive heel enthesitis refractory to standard treatment. Patients were randomized to receive subcutaneous secukinumab 150/300 mg or placebo. Read More

View Article and Full-Text PDF

Axial psoriatic arthritis: new entity or simple clinical form?

Joint Bone Spine 2022 May 13:105409. Epub 2022 May 13.

Service de Rhumatologie, CHRU, Boulevard Fleming, 25030 Besançon, France; EA 4267 PEPITE, Université Bourgogne Franche-Comté, Besançon, France.

View Article and Full-Text PDF

Untargeted Metabolomics Profiling Identifies Onycholysis-Specific Signature in Psoriasis.

Joint Bone Spine 2022 May 13:105410. Epub 2022 May 13.

Service de Biochimie et Biologie moléculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Laboratoire CarMeN, INSERM U1060, INRAE U1397, Université de Lyon, Université Claude Bernard Lyon1, 69600, Oullins, France.

View Article and Full-Text PDF

Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning.

Front Med (Lausanne) 2022 28;9:891863. Epub 2022 Apr 28.

Knowledge Engineering Institute, Universidad Autónoma de Madrid, Madrid, Spain.

Objectives: To identify patient- and disease-related characteristics that make it possible to predict higher disease severity in recent-onset PsA.

Methods: We performed a multicenter observational prospective study (2-year follow-up, regular annual visits). The study population comprised patients aged ≥ 18 years who fulfilled the CASPAR criteria and less than 2 years since the onset of symptoms. Read More

View Article and Full-Text PDF

Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality.

Rheumatology (Oxford) 2022 May 14. Epub 2022 May 14.

CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University, School of Medicine, Tenovus Building, Heath Park Campus, Cardiff, CF14 4XN.

Objectives: Investigate whether individuals with inflammatory arthritis, their treatments and shielding status affect the risk of adverse outcomes from COVID-19 for the entire population of Wales, U.K.

Methods: Retrospective, population-based cohort study using linked, anonymised electronic health data from SAIL Databank, including primary/secondary care, rheumatology, Office for National Statistics Mortality and COVID-19 laboratory data. Read More

View Article and Full-Text PDF

Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis.

Intern Med J 2022 May 14. Epub 2022 May 14.

Monash-Cabrini Department of Musculoskeletal Health and Clinical Epidemiology, Cabrini Health, Melbourne, Australia.

Biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) have been an important advance in the management of inflammatory arthritis, but are expensive medications, carry a risk of infection and other adverse effects, and are often perceived as a burden by patients. We used GRADE methodology to develop recommendations for dose reduction and discontinuation of b/tsDMARDs in people with rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA) who have achieved a low disease activity state or remission. The recommendations form part of the Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis, an NHMRC-endorsed 'living' guideline, in which recommendations are updated in near real-time as new evidence emerges. Read More

View Article and Full-Text PDF

Usefulness of Ultrasound Examination in the Assessment of the Nail Apparatus in Psoriasis.

Int J Environ Res Public Health 2022 May 5;19(9). Epub 2022 May 5.

Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-900 Olsztyn, Poland.

The assessment of psoriatic nail changes in everyday practice is based exclusively on clinical symptoms that do not reflect the entire disease process in the nail apparatus. The use of imaging methods, especially widely available and inexpensive ultrasonography, creates the possibility of additional revealing and assessing grayscale of morphological changes of the ventral nail plate, nail bed, and matrix, as well as the attachment of the finger extensor tendon to the distal phalanx. What is more, it enables the assessment of inflammation severity in the power Doppler technique. Read More

View Article and Full-Text PDF

Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil.

Front Pharmacol 2022 26;13:878972. Epub 2022 Apr 26.

Pharmaceutical Services Graduate Program, Federal University of Espírito Santo, Alegre, Brazil.

Conventional synthetic disease-modifying antirheumatic drugs are the first-line treatment to inhibit the progression of psoriatic arthritis. Despite their widespread clinical use, few studies have been conducted to compare these drugs for psoriatic arthritis. a longitudinal study was carried out based on a centered patient national database in Brazil. Read More

View Article and Full-Text PDF

IL-23 Monoclonal Antibodies for IBD: So Many, So Different?

J Crohns Colitis 2022 May;16(Supplement_2):ii42-ii53

University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.

Interleukin [IL]-23 is a member of the IL-12 family of cytokines and has been implicated in multiple inflammatory disorders including psoriasis, psoriatic arthritis, and the inflammatory bowel diseases [IBDs]. Blockade of both IL-12 and IL-23 using an antibody that targets a shared subunit is highly effective in treating psoriasis, and recent data suggest similar efficacy in IBD with minimal adverse events. In this review, we summarise published data on the efficacy of anti-IL-12/23 therapies in IBD as well as emerging data on more selective anti-IL-23 specific therapies. Read More

View Article and Full-Text PDF

What Can IBD Specialists Learn from IL-23 Trials in Dermatology?

J Crohns Colitis 2022 May;16(Supplement_2):ii20-ii29

Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.

Background And Aims: The advent of biologic drugs revolutionised the treatment of many chronic inflammatory diseases in rheumatology, dermatology, and gastroenterology. The introduction of different targeted agents closely followed the increase in knowledge of pathogenic mechanisms. The identification of IL-23 as a master regulator of 'pathogenic' inflammation and the consequent efficacy of IL-23 blocking agents were first proofed in psoriasis and then in other inflammatory diseases such as psoriatic arthritis and Crohn's disease. Read More

View Article and Full-Text PDF

Do Patients with Psoriatic Arthritis Have More Severe Skin Disease than Patients with Psoriasis Only? A Systematic Review and Meta-Analysis.

Dermatology 2022 May 12:1-12. Epub 2022 May 12.

Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Background: Early identification of patients at risk of psoriatic arthritis (PsA) is essential to facilitate early diagnosis and improve clinical outcomes. Severe cutaneous psoriasis has been proposed to be associated with PsA, but a recent assessment of the evidence is lacking. Therefore, in this systematic review, we address the association of psoriasis skin severity with the presence and development of PsA. Read More

View Article and Full-Text PDF

Variants of beta-glucan polysaccharides downregulate autoimmune inflammation.

Commun Biol 2022 May 12;5(1):449. Epub 2022 May 12.

Medical Inflammation Research, MediCity Research Laboratory, University of Turku, FI-20520, Turku, Finland.

Common infections and polysaccharides, from bacteria and yeasts, could trigger psoriasis and psoriatic arthritis (PsA), and possibly rheumatoid arthritis (RA). The objective of this study was to investigate the effects of β-glucan polysaccharides in the effector phase of arthritis and as regulators of psoriasis and PsA-like symptoms in mice. Collagen antibody induced arthritis was studied as a model of RA and mannan-induced psoriasis (MIP) was used as model for psoriasis and PsA, using mice with a mutation of Ncf1 on the B10. Read More

View Article and Full-Text PDF

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.

Ann Rheum Dis 2022 May 12. Epub 2022 May 12.

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK

Objective: To develop EULAR points-to-consider for therapeutic drug monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases (RMDs).

Methods: The points-to-consider were developed in accordance with EULAR standardised operation procedures by a multidisciplinary task force from eight European countries, based on a systematic literature review and expert consensus. Level of evidence and strength of the points-to-consider were determined, and mean levels of agreement among the task force were calculated using a 10-point rating scale. Read More

View Article and Full-Text PDF

A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry.

Eur J Rheumatol 2022 Apr;9(2):82-87

Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey.

Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018.

Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Read More

View Article and Full-Text PDF

Expert recommendations for the use of apremilast in psoriatic arthritis.

Reumatol Clin (Engl Ed) 2022 May 7. Epub 2022 May 7.

Hospital Universitario Parc Taulí, Departamento de Medicina, Universidad Autónoma de Barcelona, Sabadell, Barcelona, Spain.

Introduction And Objectives: Despite the evidence, there are doubts about the positioning of apremilast in the psoriatic arthritis (PsA) treatment algorithm. The objective of this project was to collect the scientific evidence and the experience of a group of rheumatologists who are experts in the management of PsA with apremilast in clinical practice in Spain.

Material And Methods: A scientific committee made up of 6 experts proposed 5 clinical scenarios where the evidence on the use of apremilast in PsA was controversial: (i) Efficacy in peripheral PsA; (ii) Efficacy in enthesitis and dactylitis; (iii) Efficacy in PsA with skin involvement; (iv) Comorbidities; and (v) Apremilast safety. Read More

View Article and Full-Text PDF

A multicentre validation study of a smartphone application to screen hand arthritis.

BMC Musculoskelet Disord 2022 May 9;23(1):433. Epub 2022 May 9.

, Perth, Australia.

Background: Arthritis is a common condition, and the prompt and accurate assessment of hand arthritis in primary care is an area of unmet clinical need. We have previously developed and tested a screening tool combining machine-learning algorithms, to help primary care physicians assess patients presenting with arthritis affecting the hands. The aim of this study was to assess the validity of the screening tool among a number of different Rheumatologists. Read More

View Article and Full-Text PDF

[Therapeutic effects of complex multimodal rheumatologic treatment in the Rheumatology Center, Rhineland-Palatinate].

Z Rheumatol 2022 May 9. Epub 2022 May 9.

Rheumazentrum Rheinland-Pfalz GmbH, Kaiser-Wilhelm-Str. 9-11, 55543, Bad Kreuznach, Deutschland.

Introduction: The concept of complex multimodal rheumatologic treatment (CMRT) has been established for several years in German rheumatologic departments and aims at a multifaceted therapeutic approach to patients with rheumatic diseases. Objective of this study was to examine the therapeutic effect of CMRT in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in an acute rheumatology center.

Methods: The treatment success of CMRT was evaluated by epidemiologic data, patient questionnaires on visual analog scales (VAS) regarding morning stiffness, pain and disease activity (DA), as well as clinical scores (Disease Activity Score 28 [DAS28], Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], Bath Ankylosing Spondylitis Functional Index [BASFI]), laboratory inflammation markers (CRP, erythrocyte sedimentation rate) and medication in three visits: visit 1 = begin of CMRT; visit 2 = end of CMRT; visit 3 = 3 months after CMRT. Read More

View Article and Full-Text PDF

Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis.

Rheumatol Int 2022 May 9. Epub 2022 May 9.

Department of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa Mitaka, Tokyo, 181-8611, Japan.

The purpose of this study was to clarify the clinical characteristics of spondyloarthritis (SpA) patients with inflammatory bowel disease (IBD) compared to those without IBD. Furthermore, among patients with SpA and IBD, we aimed to clarify what clinical characteristics lead rheumatologists to diagnose "IBD-related arthritis." Utilizing SpA and psoriatic arthritis (PsA) patients' data from an international, cross-sectional, observational study, we analyzed information on demographics and disease characteristics, dichotomizing patients by IBD status. Read More

View Article and Full-Text PDF

Sex-Based Medicine Meets Psoriatic Arthritis: Lessons Learned and to Learn.

Front Immunol 2022 22;13:849560. Epub 2022 Apr 22.

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.

Humorally associated autoimmune diseases generally show a female predominance whereas ankylosing spondylitis, a disease that overlaps with psoriatic arthritis (PsA), shows a male predominance. The present review ascertains the current knowledge of sex-specific differences related to psoriatic arthritis (PsA), a chronic, inflammatory condition associated with psoriasis. Sex differences may have important implications for clinical research in PsA and in terms of epidemiology (incidence, prevalence, lifetime risk, survival, and mortality), clinical, radiological, and laboratory features, and response to treatment. Read More

View Article and Full-Text PDF

Orphan Nuclear Receptor NR4A2 Is Constitutively Expressed in Cartilage and Upregulated in Inflamed Synovium From hTNF-Alpha Transgenic Mice.

Front Pharmacol 2022 20;13:835697. Epub 2022 Apr 20.

Department of Biological Sciences, Loyola University New Orleans, New Orleans, LA, United States.

Orphan nuclear receptor 4A2 (NR4A2/Nurr1) is a constitutively active transcription factor with potential roles in the onset and progression of inflammatory arthropathies. NR4A2 is overexpressed in synovium and cartilage from individuals with rheumatoid arthritis (RA), psoriatic arthritis, and osteoarthritis. This study documents the expression and tissue localization of NR4A2 and upstream regulator nuclear factor kappa B (NF-κB) in the human tumor necrosis factor-alpha (hTNF-α) transgenic mouse model of RA. Read More

View Article and Full-Text PDF

Psoriatic arthritis.

Med Clin (Barc) 2022 May 4. Epub 2022 May 4.

Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.

Psoriatic arthritis (PsA) is a type of inflammatory arthritis that is included within the spondyloarthritis, a group of rheumatological diseases characterized by different clinical manifestations and associated comorbidities, that can compromise the quality of life of patients. The diagnosis of PsA is sometimes difficult due to an enormous clinical and radiological variability, including six different domains of involvement: peripheral joint, axial skeleton, skin psoriasis, nail psoriasis, enthesitis and dactylitis. Currently, there are no biomarkers that allow the detection of PsA in patients with psoriasis, so a high level of suspicion is important, mainly by dermatologists, but also by other specialists, such as family doctors. Read More

View Article and Full-Text PDF

Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries.

RMD Open 2022 May;8(1)

INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.

Objectives: Patient care can vary substantially by country. The objective was to explore differences in psoriatic arthritis (PsA) across countries for disease activity, impact and treatments.

Methods: A cross-sectional analysis of 13 countries from the Remission/Flare in PsA study (NCT03119805) of consecutive adult patients with definite PsA was performed. Read More

View Article and Full-Text PDF

Comparative risk of herpes zoster in patients with psoriatic disease on systemic treatments: a systematic review and network meta-analysis.

Ther Adv Chronic Dis 2022 2;13:20406223221091188. Epub 2022 May 2.

Department of Dermatology, Chang Gung Memorial Hospital Linkou Branch, No.5, Fuxing St., Guishan Dist., Taoyuan City 333.

Background: Numerous previous studies have examined risk of herpes zoster (HZ) in psoriatic disease; however, the results of these studies are conflicting and the relative risks associated with different treatments remain largely unknown. In this meta-analysis, we examined the relative risk of HZ associated with systemic treatments for psoriatic disease.

Methods: PubMed, EMBASE, Cochrane Library, and Web of Science databases were searched to identify relevant English-language studies published up to April 2021. Read More

View Article and Full-Text PDF